ANTIBODIES AND ANTI-ANTIBODIES TO STEROID HORMONES, AND BREAST CANCER RISK

Antibodies against sex steroid hormones are known to modulate their serum concentration and inhibit experimental breast cancer (BC). Hence, these effects could be changed by according anti-idiotypic antibodies. However, relationships between antibodies and anti-idiotypic antibodies and BC in women...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. N. Glushkov, E. G. Polenok, M. V. Kostyanko, A. V. Antonov, N. E. Verzhbitskaya, I. A. Vafin, S. E. Ragozhina
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2017
Materias:	breast cancer antibodies anti-idiotypic antibodies estradiol progesterone carcinogenesis Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/d6649d750d474cfb9d1df4f9caad4081
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d6649d750d474cfb9d1df4f9caad4081
record_format	dspace
spelling	oai:doaj.org-article:d6649d750d474cfb9d1df4f9caad40812021-11-18T08:03:46ZANTIBODIES AND ANTI-ANTIBODIES TO STEROID HORMONES, AND BREAST CANCER RISK1563-06252313-741X10.15789/1563-0625-2017-5-577-584https://doaj.org/article/d6649d750d474cfb9d1df4f9caad40812017-10-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1359https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAntibodies against sex steroid hormones are known to modulate their serum concentration and inhibit experimental breast cancer (BC). Hence, these effects could be changed by according anti-idiotypic antibodies. However, relationships between antibodies and anti-idiotypic antibodies and BC in women are still poorly studied. The aim of this study was to identify possible associations between occurrence of antibodies against estradiol and progesterone (IgG-Es1and IgG-Pg1) and according antiidiotypic antibodies (IgG-Es2 and IgG-Pg2), and postmenopausal BC. Eighty-nine healthy women and 273 BC patients were examined. A non-competitive solid phase immunoassay for IgG-Es1 and IgG-Pg1 was performed using estradiol and progesterone conjugates with bovin serum albumin as antigens. Monoclonal antibodies against Es and Pg as antigens have been used for noncompetitive solid phase immunoassay of IgG-Es2 and IgG-Pg2. Results: absence of both IgG-Es1 and IgG-Pg1 was revealed in 53.9% of healthy donors and 41.0% of BC patients (p = 0.04; OR = 0.6). Presence of IgG-Es1 without IgG-Pg1, or IgG-Pg1 without IgG-Es1was detected for, respectively, 15.7% and 20.2% of healthy women, and in 10.3% and 7.7% of BC patients (p > 0.05). Simultaneous increase of both IgG-Es1 and IgG-Pg1 was revealed in 10.1% of healthy donors and in 41.0% of BC patients (p < 0.0001; OR = 5.3). Absence of a single antibogy (IgG-Es2 or IgG-Pg2) showed similar frequency in the groups under study. Simultaneous increase of both IgG-Es2 and IgG-Pg2 was detected in 52.8% of healthy women and 34.8% of BC patients (p = 0.03; OR = 0.4). Conclusion: We have first revealed an immunostimulating synergistic effect of antibodies against sex steroid hormones and immunoinhibitory synergistic effect of appropriate anti-idiotypic antibodies upon the postmenopausal breast cancer risk.A. N. GlushkovE. G. PolenokM. V. KostyankoA. V. AntonovN. E. VerzhbitskayaI. A. VafinS. E. RagozhinaSPb RAACIarticlebreast cancerantibodiesanti-idiotypic antibodiesestradiolprogesteronecarcinogenesisImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 19, Iss 5, Pp 577-584 (2017)
institution	DOAJ
collection	DOAJ
language	RU
topic	breast cancer antibodies anti-idiotypic antibodies estradiol progesterone carcinogenesis Immunologic diseases. Allergy RC581-607
spellingShingle	breast cancer antibodies anti-idiotypic antibodies estradiol progesterone carcinogenesis Immunologic diseases. Allergy RC581-607 A. N. Glushkov E. G. Polenok M. V. Kostyanko A. V. Antonov N. E. Verzhbitskaya I. A. Vafin S. E. Ragozhina ANTIBODIES AND ANTI-ANTIBODIES TO STEROID HORMONES, AND BREAST CANCER RISK
description	Antibodies against sex steroid hormones are known to modulate their serum concentration and inhibit experimental breast cancer (BC). Hence, these effects could be changed by according anti-idiotypic antibodies. However, relationships between antibodies and anti-idiotypic antibodies and BC in women are still poorly studied. The aim of this study was to identify possible associations between occurrence of antibodies against estradiol and progesterone (IgG-Es1and IgG-Pg1) and according antiidiotypic antibodies (IgG-Es2 and IgG-Pg2), and postmenopausal BC. Eighty-nine healthy women and 273 BC patients were examined. A non-competitive solid phase immunoassay for IgG-Es1 and IgG-Pg1 was performed using estradiol and progesterone conjugates with bovin serum albumin as antigens. Monoclonal antibodies against Es and Pg as antigens have been used for noncompetitive solid phase immunoassay of IgG-Es2 and IgG-Pg2. Results: absence of both IgG-Es1 and IgG-Pg1 was revealed in 53.9% of healthy donors and 41.0% of BC patients (p = 0.04; OR = 0.6). Presence of IgG-Es1 without IgG-Pg1, or IgG-Pg1 without IgG-Es1was detected for, respectively, 15.7% and 20.2% of healthy women, and in 10.3% and 7.7% of BC patients (p > 0.05). Simultaneous increase of both IgG-Es1 and IgG-Pg1 was revealed in 10.1% of healthy donors and in 41.0% of BC patients (p < 0.0001; OR = 5.3). Absence of a single antibogy (IgG-Es2 or IgG-Pg2) showed similar frequency in the groups under study. Simultaneous increase of both IgG-Es2 and IgG-Pg2 was detected in 52.8% of healthy women and 34.8% of BC patients (p = 0.03; OR = 0.4). Conclusion: We have first revealed an immunostimulating synergistic effect of antibodies against sex steroid hormones and immunoinhibitory synergistic effect of appropriate anti-idiotypic antibodies upon the postmenopausal breast cancer risk.
format	article
author	A. N. Glushkov E. G. Polenok M. V. Kostyanko A. V. Antonov N. E. Verzhbitskaya I. A. Vafin S. E. Ragozhina
author_facet	A. N. Glushkov E. G. Polenok M. V. Kostyanko A. V. Antonov N. E. Verzhbitskaya I. A. Vafin S. E. Ragozhina
author_sort	A. N. Glushkov
title	ANTIBODIES AND ANTI-ANTIBODIES TO STEROID HORMONES, AND BREAST CANCER RISK
title_short	ANTIBODIES AND ANTI-ANTIBODIES TO STEROID HORMONES, AND BREAST CANCER RISK
title_full	ANTIBODIES AND ANTI-ANTIBODIES TO STEROID HORMONES, AND BREAST CANCER RISK
title_fullStr	ANTIBODIES AND ANTI-ANTIBODIES TO STEROID HORMONES, AND BREAST CANCER RISK
title_full_unstemmed	ANTIBODIES AND ANTI-ANTIBODIES TO STEROID HORMONES, AND BREAST CANCER RISK
title_sort	antibodies and anti-antibodies to steroid hormones, and breast cancer risk
publisher	SPb RAACI
publishDate	2017
url	https://doaj.org/article/d6649d750d474cfb9d1df4f9caad4081
work_keys_str_mv	AT anglushkov antibodiesandantiantibodiestosteroidhormonesandbreastcancerrisk AT egpolenok antibodiesandantiantibodiestosteroidhormonesandbreastcancerrisk AT mvkostyanko antibodiesandantiantibodiestosteroidhormonesandbreastcancerrisk AT avantonov antibodiesandantiantibodiestosteroidhormonesandbreastcancerrisk AT neverzhbitskaya antibodiesandantiantibodiestosteroidhormonesandbreastcancerrisk AT iavafin antibodiesandantiantibodiestosteroidhormonesandbreastcancerrisk AT seragozhina antibodiesandantiantibodiestosteroidhormonesandbreastcancerrisk
_version_	1718422384315203584

ANTIBODIES AND ANTI-ANTIBODIES TO STEROID HORMONES, AND BREAST CANCER RISK

Ejemplares similares